Skip to content

Clinical significance and molecular mechanism of Wendan Decoction in early intervention of phlegm-dampness metabolic syndrome

Clinical significance and molecular mechanism of Wendan Decoction in early intervention of phlegm-dampness metabolic syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005829
Enrollment
Unknown
Registered
2022-04-09
Start date
2022-04-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

treatment group:Wendan Decoction+lifestyle
control group:Wendan Decoction placebo+lifestyle

Sponsors

Shunde District Hospital of Chinese Medicine of Foshan City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) those who meet the diagnostic criteria of metabolic syndrome and belong to TCM phlegm-dampness constitution; (2) those who have not received any corresponding medication for blood pressure, and/or lipids, and/or blood glucose; (3) Aged between 18 and 70; (4) The informed consent is signed.

Exclusion criteria

Exclusion criteria: (1) secondary blood pressure, and/or lipids, and/or elevated blood sugar or obesity due to other diseases; (2) patients with excessive blood pressure, and/or blood lipid, and/or blood glucose elevation, or complications, which are not suitable for simple lifestyle intervention and need immediate drug intervention; (3) those who are taking or have taken traditional Chinese medicine decoction or patent Chinese medicine with similar effect in recent 1 month; (4) those who are pregnant, breast-feeding or have pregnancy needs; (5) allergic constitution or allergic history to the taste of Wendan Decoction;

Design outcomes

Primary

MeasureTime frame
The rate of metabolic index returning to normal;

Secondary

MeasureTime frame
chinese medicine therapeutic effect;Adverse drug reactions;

Countries

China

Contacts

Public ContactWang Dawei
sdyybg@21.cn.com13923246233

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026